KALBE PHARMA (largest pharmaceutical company in Indonesia)
and FAES FARMA have signed a licence agreement for the
commercialization of Bilastine in Indonesia by Kalbe.
Indonesian pharmaceutical market is one of the major emerging
markets in Asia with annual growth rates between 12% and
15,5% during the last four years in a country with 230
million people.
Kalbe Pharma is the largest publicly listed pharmaceutical
company in Southeast Asia leading the Indonesian
pharmaceutical market with a market share of 13% in
prescription drugs and of 14% in OTC products. Employs over
10.000 people and has a sale force of over 4.000 people,
2.300 being medical representatives for the prescription
drugs market.
Bilastine is a latest generation antihistaminic, indicated for the symptomatic treatment of allergic rhinoconjuntivitis and urticaria, with a rapid onset, long- lasting action and a wide safety profile.
Bilastine Licensees
It must be highlighted that Bilastine has been licensed to
top leading Companies all over the world:
- Pfizer (with the first position in the worldwide ranking)
in Mexico and
Turkey.
- Glaxo-GSK(number four in the worldwide ranking) in Spain
and Poland.
- Takeda-Nycomed (with the tenth position in the worldwide
ranking) in
Brazil.
- Merck-Serono in India
- Menarini (first Italian pharmaceutical company) in Italy,
50 European and
CIS countries (Commonwealth of Independent States).
- Vianex (first Greek pharmaceutical company) as a second
licence in
Greece.
- Pierre Fabre (second French pharmaceutical company), as a
second licence in France.
- Yuhan (second Korean pharmaceutical company), in South
Korea.
- Hikma (fifth largest pharmaceutical company in the Middle
East and
North African countries-MENA) in the MENA countries.
- Kalbe (first pharmaceutical company) in Indonesia
FAES is actively making arrangements to grant licences in
additional Asian markets, especially Japan (first
antihistamine market in the world, under negotiation), China
and the remaining Southeast Asian countries.
The Product has already been approved in 28 countries: 25
countries within the
European Economic Area (EEA) as well as in Brazil, Colombia
and Guatemala.
The commercialization started in April 2011 in the Spanish
market, first relevant market, and in five months the
molecule has reached a market share close to 11% which has
lead Bilastine to being the most successful antihistaminic
during a launch stage in Spain.
November 10th, 2011.